Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Zealand Pharma A/S (ZLDPF) had Revenue of $9.09M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$9.09M
Net Income	$-156.43M
Cost of Goods Sold	$1.14M
Gross Profit	$7.95M
Operating Expenses	$193.56M
Operating Income	$-184.47M
Non-Operating Income/Expense	$27.37M
Pre-Tax Income	$-157.10M
Normalized Pre-Tax Income	$-157.10M
Income after Taxes	$-156.43M
Income from Continuous Operations	$-156.43M
Consolidated Net Income/Loss	$-156.43M
Normalized Income after Taxes	$-156.43M
EBIT	$-184.47M
EBITDA	$-180.72M
Weighted-Average Shares Outstanding (Basic)	66.43M
Weighted-Average Shares Outstanding (Diluted)	66.43M
Earnings per Share (EPS) (Basic)	$-2.35
Earnings per Share (EPS) (Diluted)	$-2.35
Balance Sheet Financials
Current Assets	$1.24B
Property, Plant, and Equipment	$6.74M
Long-Term Assets	$141.79M
Total Assets	$1.38B
Current Liabilities	$58.50M
Long-Term Debt	$41.37M
Long-Term Liabilities	$70.38M
Total Liabilities	$128.88M
Common Equity	$1.25B
Tangible Shareholders Equity	$1.25B
Shareholders Equity	$1.25B
Common Shares Outstanding	71.02M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-134.97M
Cash Flow from Investing Activities	$-1.06B
Cash Flow from Financial Activities	$1.20B
Beginning Cash	$65.15M
End Cash	$69.64M
Increase/Decrease in Cash	$4.49M
Stock-Based Compensation	$12.62M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	21.14
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.03
Debt to Equity Ratio	0.03
Gross Margin	87.44%
Operating Margin	-2029.33%
EBIT Margin	-2029.33%
EBITDA Margin	-1988.10%
Pre-Tax Profit Margin	-1728.23%
Profit Margin	-1720.87%
Free Cash Flow	$-136.43M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.01
Inventory Turnover	0.74
Receiveable Turnover	0.22
Days Sales in Receivables	1694.24
Return on Equity	-12.52%
Return on Tangible Equity	-12.54%
Return on Assets	-11.35%
Return on Investments	-12.12%
Book Value Per Share	$17.59
Free Cash Flow per Share	$-2.05
Operating Cash Flow per Share	$-2.03

Data from Zacks Investment Research, Inc.